Literature DB >> 29943129

Conservative management of endometrial cancer: a survey amongst European clinicians.

M La Russa1, I Zapardiel2, M J Halaska3, K Zalewski4,5,6, R Laky7, P Dursun8, D Lindquist9, V Sukhin10, S Polterauer11, I Biliatis12.   

Abstract

OBJECTIVE: To investigate differences and similarities in the clinical approach of young clinicians managing women with endometrial cancer (EC) conservatively.
METHODS: A web-based survey was carried out. A platform of the European Network of Young Gynaecological Oncologists (ENYGO) database was used. A 38-item multiple-choice questionnaire was used to evaluate current practice in fertility-sparing management of EC. The survey covered investigations, treatment options, follow-up and management of recurrence and future family planning. Descriptive statistics were used.
RESULTS: Overall, 116 out of 650 (17.84%) ENYGO members responded to the survey. In 92 (79.3%) centres, the caseload of early stage EC treated conservatively was less than 10 per year. One hundred and seven responders (93.8%) believe that treatment with progestins could be offered in grade 1 EC without myometrial invasion, but a minority would recommend it even for grade 2 tumours with no myometrial invasion or grade 1 with superficial invasion. The diagnostic tool for establishing grade of tumour was hysteroscopy with dilatation and curettage in 64 (55%) centres. Medroxyprogesterone acetate represents the most commonly prescribed progestogen (55, 47.4%). In 78 (67.2%) centres, a repeat endometrial biopsy was offered after 3 months of treatment commencement. Recurrences are treated mostly with hysterectomy (81, 69.9%) with only a small number of responders recommending to repeat progestin treatment. Lynch syndrome is a contraindication for conservative management in half of the responders (57, 49.1%). Most clinicians agree that patients should be referred promptly for assisted reproductive techniques once complete response has been achieved (68, 58.6%).
CONCLUSIONS: Our study shows that conservative management is increasingly offered to women affected by early stage EC wishing to preserve their fertility. Further studies and joint registries are required to evaluate safety and effectiveness of this approach in this probably growing number of patients.

Entities:  

Keywords:  Assisted reproduction; Conservative management; Endometrial cancer; Pregnancies; Progestins

Mesh:

Substances:

Year:  2018        PMID: 29943129     DOI: 10.1007/s00404-018-4820-7

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  The reproductive prognosis of women considering fertility preservation for early stage endometrial cancer.

Authors:  Pietro Gambadauro
Journal:  Arch Gynecol Obstet       Date:  2019-01-04       Impact factor: 2.344

2.  National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.

Authors:  Ross F Harrison; Weiguo He; Shuangshuang Fu; Hui Zhao; Charlotte C Sun; Rudy S Suidan; Terri L Woodard; J Alejandro Rauh-Hain; Shannon N Westin; Sharon H Giordano; Larissa A Meyer
Journal:  Am J Obstet Gynecol       Date:  2019-05-22       Impact factor: 8.661

Review 3.  The Perspectives of Fertility Preservation in Women with Endometrial Cancer.

Authors:  Jure Knez; Leyla Al Mahdawi; Iztok Takač; Monika Sobočan
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

4.  Hsa_Circ_0001860 Promotes Smad7 to Enhance MPA Resistance in Endometrial Cancer via miR-520h.

Authors:  Shuang Yuan; Panchan Zheng; Xiao Sun; Judan Zeng; Wenjiao Cao; Wuyuan Gao; Yudong Wang; Lihua Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-29

5.  Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.

Authors:  Erica Herrera Cappelletti; Jonas Humann; Rafael Torrejón; Pietro Gambadauro
Journal:  Hum Reprod Update       Date:  2022-02-28       Impact factor: 15.610

Review 6.  Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.

Authors:  Nayanar-Adela Contreras; Jordi Sabadell; Paula Verdaguer; Carla Julià; Maria-Eulalia Fernández-Montolí
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

7.  The Metabolomic Approach for the Screening of Endometrial Cancer: Validation from a Large Cohort of Women Scheduled for Gynecological Surgery.

Authors:  Jacopo Troisi; Antonio Mollo; Martina Lombardi; Giovanni Scala; Sean M Richards; Steven J K Symes; Antonio Travaglino; Daniele Neola; Umberto de Laurentiis; Luigi Insabato; Attilio Di Spiezio Sardo; Antonio Raffone; Maurizio Guida
Journal:  Biomolecules       Date:  2022-09-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.